JNJ
Johnson & Johnson MedTech (NYSE: J&J) announced that its OTTAVA surgical robot secured de novo FDA...
Article Summary
HOLD- Johnson & Johnson MedTech (NYSE: J&J) announced that its OTTAVA surgical robot secured de novo FDA classification, paving the way for entry into the U.S. surgical robotics market.
- J&J plans to launch the soft tissue robotic system with select select US customers and advance into additional indications and regulatory jurisdictions over time.
- Intuitive Surgical (NASDAQ: INSX) and Microbot (OTTAVA) secured FDA clearance in 2025, while other competitors including CMR Surgical and Auris Health are expected to launch robotic surgical systems in 2035.
- Global data forecasts the robotic surgery market will reach $20.8 billion in valuation by 2035, up from around $12 billion in 2025.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 8.1% | 25% | 35.0 ptsBelow Screener (8.1%) - Weak growth |
| EPS Growth Next 5Y ? | 9.9% | 25% | 20.0 ptsWeak (9.9%) - Low expectations |
| Target Price Upside ? | 8.2% | 20% | 35.0 ptsBelow Screener (8.2%) - Target: $275.14 vs Current: $254.34 |
| Gross Margin % ? | 75.1% | 15% | 100.0 ptsExceptional (75.1%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -5.6% | 15% | 20.0 ptsBarely a Dip (-5.6%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About JNJ
- Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.
- It operates in two segments, Innovative Medicine and MedTech.
- The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
- The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.
- This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand.
- The company was founded in 1886 and is based in New Brunswick, New Jersey.